How the FDA Let Medications From Banned Foreign Factories Into the U.S. — ProPublica

In 2022, three food inspectors and medicines went to India to investigate the Sun Pharma massive plant, which produces dozens of genetic drugs for Americans. Within two weeks, they found dangerous breakdowns in how critical medicines were made, and the FDA eventually put the plant ban – forbidding companies to deliver drugs to the US.

However, the agency quietly gave a global manufacturer a special pass to continue sending more than a dozen drugs to Americans, although they were made at the same substandard factory that was officially banned from the US market.

It was not the first time. Here are the key trips from 14-month investigation propublica Foreign FDA:

• For ten years, the agency has instructed to defend drug supplies in America, which gave similar release from some of the most problematic foreign drug manufacturers in India, which allowed the factory banned from the US market to continue the delivery of drugs for an unsuspecting US public.

• A secret group inside the FDA has released a medicine from the ban on imports, allegedly to prevent drug deficiency. With each pass of the agency, she rejected warnings from his own inspectors about dangerous drug quality violations at the plant. Overall, the FDA launched at least 150 medicines or their ingredients from prohibited mold, invalid water, dirty laboratories, or fraudulent testing protocols. Almost everyone came from factories in India.

• The FDA has not regularly checked the medication released from the import ban to find out if they were safe or actively monitored potential damage reports among patients. And when drugs were distributed to the US, the agency kept practice largely hidden from the public. The FDA has stated that it causes protective measures, for example, requires the supervision of other manufacturers to ensure that the released medicines were safe.

• Some of the released drugs were recalled – directly to or immediately after release – from the pollution or other defects that may cause health problems. And the propublica analysis has identified more than 600 complaints in the FDA files about the released drugs only at three factories, each of which follows a few months or years after the medicine has been expelled from the import ban. The reports contain about 70 hospitalizations and nine deaths.

• Janet Woodko, who has been heading the FDA drug evaluation and drug evaluation center for more than two decades, has said it did not see the need to inform the public about drugs from prohibited factories, as the agency believed that they would be safe and that such information would create “some madness” among consumers who may seek recipes. “We had to deal with the hand we considered,” she said, noting that she supported the exceptions to combat the chronic drug deficiency.

• The decisions made by the FDA decades ago generated the use of release. In the 2000s, since the cost of drugs that arose, the FDA approved hundreds of common drugs for foreign manufacturers who were previously in trouble, a company well known to inspectors working to release safety and quality breakdowns.

• Released drugs that came to the United States include antibiotics, chemotherapy treatment, antidepressants, sedatives and epilepsy.

Sun Pharma did not respond to several requests for comment. If the FDA has banned, said the company This “will make all the necessary steps to address these issues and ensure that the regulator is completely satisfied with the company’s correction. Sun Pharma still seeks to be … compatible and provide quality products to its customers and patients in the world.”